Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
Gastroenterology and Hepatology from Bed to Bench,
Vol. 9 No. 3 (2016),
20 June 2016
,
Page 158-173
https://doi.org/10.22037/ghfbb.v0i0.952
Abstract
Metabolome analysis is used to evaluate the characteristics and interactions of low molecular weight metabolites under a specific set of conditions. In cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatotic hepatitis (NASH) the liver does not function thoroughly due to long-term damage. Unfortunately the early detection of cirrhosis, HCC, NAFLD and NASH is a clinical problem and determining a sensitive, specific and predictive novel method based on biomarker discovery is an important task. On the other hand, metabolomics has been reported as a new and powerful technology in biomarker discovery and dynamic field that cause global comprehension of system biology. In this review, it has been collected a heterogeneous set of metabolomics published studies to discovery of biomarkers in researches to introduce diagnostic biomarkers for early detection and the choice of patient-specific therapies.
- cirrhosis
- HCC
- NAFLD
- NASH
- metabolomics
How to Cite
References
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.
Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-62.
Qi SW, Tu ZG, Peng WJ, Wang LX, Ou-Yang X, Cai AJ, et al. (1)H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J Gastroenterol. 2012;18(3):285-90.
Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med. 2009;47(3):305-10.
Gomase VS, Changbhale SS, Patil SA, Kale KV. Metabolomics. Curr Drug Metab. 2008;9(1):89-98.
Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterology and Hepatology from bed to bench. 2015;8(3):215.
Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterology and Hepatology from bed to bench. 2011;4(4).
Zamanian–Azodi M, Rezaei–Tavirani M, Hasanzadeh H, RahmatiRad S, Dalilan S, Gilanchi S, et al. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterology and Hepatology from bed to bench. 2014;1(1).
Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterology and Hepatology from bed to bench. 2014;7(1).
Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterology and Hepatology from bed to bench. 2016;9(2):114.
Rezaei-Tavirani M, Zamanian-Azodi M, Rajabi S, Masoudi-Nejad A, Rostami-Nejad M, Rahmatirad S. Protein Clustering and Interactome Analysis in Parkinson and Alzheimer's Diseases. Archives of Iranian Medicine (AIM). 2016;19(2).
Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry. 2008;22(19):3061-8.
Tang H, Wang Y. Metabonomics: a revolution in progress. Sheng wu hua xue yu sheng wu wu li jin zhan. 2005;33(5):401-17.
Wojakowska A, Chekan M, Widlak P, Pietrowska M. Application of Metabolomics in Thyroid Cancer Research. International Journal of Endocrinology. 2015;2015.
Bro R, Kamstrup-Nielsen MH, Engelsen SB, Savorani F, Rasmussen MA, Hansen L, et al. Forecasting individual breast cancer risk using plasma metabolomics and biocontours. Metabolomics. 2015:1-5.
Fathi F, Ektefa F, Oskouie AA, Rostami K, Rezaei-Tavirani M, Alizadeh AHM, et al. NMR based metabonomics study on celiac disease in the blood serum. Gastroenterology and Hepatology from bed to bench. 2013;6(4):190.
Fathi F, Kasmaee LM, Sohrabzadeh K, Nejad MR, Tafazzoli M, Oskouie AA. The differential diagnosis of Crohn’s disease and celiac disease using nuclear magnetic resonance spectroscopy. Applied Magnetic Resonance. 2014;45(5):451-9.
Fathi F, Majari‐Kasmaee L, Mani‐Varnosfaderani A, Kyani A, Rostami‐Nejad M, Sohrabzadeh K, et al. 1H NMR based metabolic profiling in Crohn's disease by random forest methodology. Magnetic Resonance in Chemistry. 2014;52(7):370-6.
Fathi F, Oskouie AA, Tafazzoli M, Naderi N, Sohrabzedeh K, Fathi S, et al. Metabonomics based NMR in Crohn's disease applying PLS-DA. Gastroenterology and Hepatology from bed to bench. 2013;6(Suppl 1):S82.
Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers. 2015;20(1):5-16.
Arakaki AK, Skolnick J, McDonald JF. Marker metabolites can be therapeutic targets as well. Nature. 2008;456(7221):443-.
Wang X, Zhang A, Han Y, Wang P, Sun H, Song G, et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Molecular & Cellular Proteomics. 2012;11(8):370-80.
Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. Journal of clinical oncology. 2007;25(19):2840-6.
Zhang A, Sun H, Yan G, Wang P, Wang X. Mass spectrometry‐based metabolomics: applications to biomarker and metabolic pathway research. Biomedical Chromatography. 2015.
Khamis MM, Adamko DJ, El‐Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass spectrometry reviews. 2015.
Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. TrAC Trends in Analytical Chemistry. 2005;24(4):285-94.
Alonso A, Marsal S, Julià A. Analytical methods in untargeted metabolomics: state of the art in 2015. Frontiers in bioengineering and biotechnology. 2015;3.
Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12(145):014-0145.
Kim MY, Baik SK. Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension. The Korean Journal of Gastroenterology. 2009;54(3):143-8.
Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, et al. Application of 1H NMR‐based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Science. 2009;100(4):782-5.
Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clinical Chemistry and Laboratory Medicine. 2009;47(3):305-10.
Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS. Liver International. 2014;34(9):1428-44.
Yang T, Zheng X, Xing F, Zhuo H, Liu C. Serum Metabolomic Characteristics of Patients with Liver Cirrhotic Ascites. Integrative Medicine International. 2014;1(3):135-42.
Lin X, Zhang Y, Ye G, Li X, Yin P, Ruan Q, et al. Classification and differential metabolite discovery of liver diseases based on plasma metabolic profiling and support vector machines. Journal of separation science. 2011;34(21):3029-36.
Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Molecular BioSystems. 2009;5(8):868-76.
Shao Y, Zhu B, Zheng R, Zhao X, Yin P, Lu X, et al. Development of urinary pseudo-targeted LC-MS based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. Journal of proteome research. 2014.
Dai W, Yin P, Chen P, Kong H, Luo P, Xu Z, et al. Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis. Analytical and bioanalytical chemistry. 2014;406(18):4325-35.
Martínez-Granados B, Morales JM, Rodrigo JM, Del Olmo J, Serra MA, Ferrández A, et al. Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies. International journal of molecular medicine. 2011;27(1):111-7.
El–Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76.
Chen F, Xue J, Zhou L, Wu S, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Analytical and bioanalytical chemistry. 2011;401(6):1899-904.
Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Molecular & Cellular Proteomics. 2012;11(2):M111. 010694.
Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. Journal of proteome research. 2007;6(7):2605-14.
Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Molecular & Cellular Proteomics. 2011;10(7):M110. 004945.
Patterson AD, Maurhofer O, Beyoğlu D, Lanz C, Krausz KW, Pabst T, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer research. 2011;71(21):6590-600.
Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res. 2012;11(2):1217-27.
Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography–mass spectrometry. Journal of proteome research. 2012;11(8):4361-72.
Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai T-H, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica chimica acta. 2012;743:90-100.
Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai T-H, et al. LC–MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. Journal of proteome research. 2012;11(12):5914-23.
Zhang A, Sun H, Yan G, Han Y, Ye Y, Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clinica Chimica Acta. 2013;418:86-90.
Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault J-C, Ziol M, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clinical Cancer Research. 2012;18(24):6714-22.
Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, et al. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Analytica Chimica Acta. 2009;650(1):3-9.
Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144(5):1066-75. e1.
Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac‐Sage P, Zucman‐Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58(1):229-38.
Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. Journal of proteome research. 2011;10(4):1828-36.
Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Analytica chimica acta. 2009;648(1):98-104.
Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. Journal of Chromatography B. 2004;813(1):59-65.
Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009;49(1):306-17.
Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comparative Hepatology. 2005;4(1):10.
Guha I, Parkes J, Roderick P, Harris S, Rosenberg W. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006;55(11):1650-60.
Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical science. 2008;115:141-50.
Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine. 2002;346(16):1221-31.
Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Canadian Medical Association Journal. 2005;172(7):899-905.
Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Annals of epidemiology. 2007;17(11):863-9.
Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5(3):199-207.
Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug metabolism and pharmacokinetics. 2010;26(1):30-46.
Liang W, Lindeman JH, Menke AL, Koonen DP, Morrison M, Havekes LM, et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1β-induced chronic inflammation. Laboratory Investigation. 2014;94(5):491-502.
Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 2009;50(6):1827-38.
Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, et al. Liquid Chromatography− Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver Disease. Journal of proteome research. 2010;9(9):4501-12.
García-Canaveras JC, Donato MT, Castell JV, Lahoz A. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. Journal of proteome research. 2011;10(10):4825-34.
Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60(3):404-13.
Li S, Liu H, Jin Y, Lin S, Cai Z, Jiang Y. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. Journal of Chromatography B. 2011;879(24):2369-75.
Landel AM, Hammond WG, Meguid MM. Aspects of amino acid and protein metabolism in cancer‐bearing states. Cancer. 1985;55(S1):230-7.
O'Connell TM. The complex role of branched chain amino acids in diabetes and cancer. Metabolites. 2013;3(4):931-45.
Nezami RM, Luo Y, Di Poto C, Varghese R, Ferrarini A, Zhang C, et al. GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort. PLoS One. 2014;10(6):e0127299-e.
Zhou S, Huang C, Wei Y. The metabolic switch and its regulation in cancer cells. Science China Life Sciences. 2010;53(8):942-58.
Stirpe F, Ravaioli M, Battelli MG, Musiani S, Grazi GL. Xanthine oxidoreductase activity in human liver disease. The American journal of gastroenterology. 2002;97(8):2079-85.
Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491(7424):458-62.
Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T, et al. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. Int Immunol. 2011;23(1):29-41.
Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol. 2011;39(2):453-63.
Wall BA, Shin S-S, Chen S. Glutamate Signaling in Human Cancers: INTECH Open Access Publisher; 2013.
Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res. 2012;18(16):4240-6.
Amodio P, Angeli P, Merkel C, Menon F, Gatta A. Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. Clinical Chemistry and Laboratory Medicine. 1990;28(9):619-26.
de la Peña CA, Rozas I, Alvarez-Prechous A, Pardinas M, Paz J, Rodriguez-Segade S. Free carnitine and acylcarnitine levels in sera of alcoholics. Biochemical medicine and metabolic biology. 1990;44(1):77-83.
Cao H, Huang H, Xu W, Chen D, Yu J, Li J, et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography–mass spectrometry. Analytica chimica acta. 2011;691(1):68-75.
Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB. 2010;12(9):625-36.
Uderhardt S, Krönke G. 12/15-Lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. Journal of molecular medicine. 2012;90(11):1247-56.
Liu B, Timar J, Howlett J, Diglio C, Honn K. Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell regulation. 1991;2(12):1045-55.
Ma J, Zhang L, Zhang J, Liu M, Wei L, Shen T, et al. 15-Lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation. The international journal of biochemistry & cell biology. 2013;45(6):1031-41.
Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N, et al. Identification of a novel human eicosanoid receptor coupled to Gi/o. Journal of Biological Chemistry. 2002;277(35):31459-65.
Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nature Reviews Cancer. 2007;7(2):79-94.
Yan M, Li H, Zhu M, Zhao F, Zhang L, Chen T, et al. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133+ cancer stem-like cells in hepatocellular carcinoma. PLoS One. 2013;8(4):e61056.
Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9(171):1479-5876.
Constantinou MA, Theocharis SE, Mikros E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicology and applied pharmacology. 2007;218(1):11-9.
Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 2012;7(7):e41456.
Goetzl EJ. Pleiotypic mechanisms of cellular responses to biologically active lysophospholipids. Prostaglandins & other lipid mediators. 2001;64(1):11-20.
Kita T, Kume N, Ishii K, Horiuchi H, Arai H, Yokode M. Oxidized LDL and expression of monocyte adhesion molecules. Diabetes research and clinical practice. 1999;45(2):123-6.
Barnes S, Gallo GA, Trash DB, Morris JS. Diagnositic value of serum bile acid estimations in liver disease. J Clin Pathol. 1975;28(6):506-9.
Barnes S, Gallo G, Trash D, Morris J. Diagnositic value of serum bile acid estimations in liver disease. Journal of clinical pathology. 1975;28(6):506-9.
Neale G, Lewis B, Weaver V, Panveliwalla D. Serum bile acids in liver disease. Gut. 1971;12(2):145-52.
Festi D, Labate AMM, Roda A, Bazzoli F, Frabboni R, Rucci P, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology. 1983;3(5):707-13.
Gowda GN. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomarkers in medicine. 2010;4(2):299-314.
Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and biophysical research communications. 2002;298(5):714-9.
Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nature reviews Drug discovery. 2008;7(8):678-93.
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484-9.
- Abstract Viewed: 1850 times
- PDF Downloaded: 389 times